Corcept Therapeutics Inc. Stock
A loss of -1.190% shows a downward development for Corcept Therapeutics Inc..
Corcept Therapeutics Inc. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
As a result the target price of 35 € shows a positive potential of 47.99% compared to the current price of 23.65 € for Corcept Therapeutics Inc..
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Corcept Therapeutics Inc. | -1.190% | 1.112% | 0.810% | 8.486% | -21.167% | 35.920% | - |
Rockwell Medical Inc. | - | 4.173% | -3.028% | -41.663% | -15.052% | -82.062% | -97.289% |
Avid Bioservices Inc | 1.940% | 9.722% | 26.400% | -52.410% | 29.508% | -52.410% | 134.456% |
Gritstone Oncology Inc | -3.330% | 11.318% | -0.776% | -62.863% | -51.830% | -88.331% | - |
Comments
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $38.00 to $40.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $42.00 to $44.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat